J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to Buy Under ...

The news keeps getting better for the new GLP-1 weight-loss drugs fromEli Lilly and Novo Nordisk.

intensifying the company’s race with Novo Nordisk to develop longer-acting insulins. Lilly’s once-weekly insulin, efsitora alfa, reduced the A1C measure of blood sugar comparably to daily ...

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on September 2 and set a price target of DKK715.00. The company’s shares closed last Monday ...

Bengaluru: Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 ...

All dos­es of No­vo Nordisk’s Ozem­pic are ex­pect­ed to face “in­ter­mit­tent short­ages” in Eu­rope dur­ing the fourth quar­ter of the year, es­pe­cial­ly low­er dos­es, ...

Update: Adds company statement about Ozempic availability in the U.S. Novo Nordisk (NVO) has said in a note published by the European Medicines Agency that the supply shortage of its diabetes drug ...

Late last year, Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. Still ...

Sept 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected ...

But the Australian missionary, who has become a naturalised PNG citizen because of the decades he spent doing missionary work in PNG, would not back down. At a meeting for the church clergy in East ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are big pharma peers. They're also each other's biggest rivals, especially in the all-important market for weight-loss drugs, in which both are ...